Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial: 6.5-study year follow-up data

被引：0

作者：

Wolinsky, J. S. ^{[1
]}

Brochet, B. ^{[2
]}

Hartung, H. -P. ^{[3
,4
]}

Naismith, R. T. ^{[5
]}

Airas, L. ^{[6
]}

Coutant, K. ^{[7
]}

Koendgen, H. ^{[7
]}

Manfrini, M. ^{[7
]}

Mehta, L. ^{[8
]}

Prajapati, K. ^{[9
]}

Kappos, L. ^{[10
]}

机构：

[1] McGovern Med Sch, Houston, TX USA

[2] Univ Bordeaux, Bordeaux, France

[3] Heinrich Heine Univ Dusseldorf, Ctr Neurol & Neuropsychiat, Dusseldorf, Germany

[4] Heinrich Heine Univ Dusseldorf, LVR Klinikum, Dusseldorf, Germany

[5] Washington Univ, Sch Med, St Louis, MO USA

[6] Univ Turku, Div Clin Neurosci, Turku, Finland

[7] F Hoffmann La Roche Ltd, Basel, Switzerland

[8] Genentech Inc, San Francisco, CA 94080 USA

[9] GCE Solut Inc, Amsterdam, Netherlands

[10] Univ Hosp Basel, Basel, Switzerland

来源：

MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

159

引用

页码：56 / 57

页数：2

共 34 条

[1] Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial
Wolisnky, J. S.
Brochet, B.
Montalban, X.
Naismith, R. T.
Manfrini, M.
Garas, M.
Villoslada, P.
Model, F.
Hubeaux, S.
Kappos, L.
Hauser, S. L.
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 490 - 491
[2] Sustained Reduction in Confirmed Disability Progression in Patients with Primary Progressive MS Treated with Ocrelizumab: 6.5-study Year Follow-up Data
Wolinsky, Jerry S.
Brochet, Bruno
Hartung, Hans-Peter
Naismith, Robert T.
Airas, Laura
Coutant, Karine
Koendgen, Harold
Manfrini, Marianna
Overell, James
Sauter, Annette
Prajapati, Kalpesh
Kappos, Ludwig
NEUROLOGY, 2020, 94 (15)
[3] Sustained Reduction In Confirmed Disability Progression In Primary Progressive Ms Patients Treated With Ocrelizumab: 6.5-study Year Follow-up Data
Wolinsky, J. S.
Brochet, B.
Hartung, H.
Naismith, R. T.
Airas, L.
Coutant, K.
Koendgen, H.
Manfrini, M.
Wang, Q.
Kappos, L.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 49 - 50
[4] Sustained and durable reduction in confirmed disability progression in patients with primary progressive multiple sclerosis receiving ocrelizumab: findings from the phase III ORATORIO study extended control period
Wolinsky, J. S.
Montalban, X.
Hauser, S. L.
Model, F.
Deol-Bhullar, G.
Garren, H.
Kappos, L.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 656 - 657
[5] Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis
Wolinsky, J. S.
Brochet, B.
Hartung, H. P.
Naismith, R. T.
Airas, L.
Coutant, K.
Koendgen, H.
Manfrini, M.
Mehta, L.
Prajapati, K.
Kappos, L.
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
[6] Sustained reduction in 48-week confirmed disability progression in patients with ppms treated with ocrelizumab in the oratorio ole: 7-year follow-up
Wolinsky, J.
Vermersch, P.
Hartung, H. P.
Naismith, R. T.
Airas, L.
Coutant, K.
Koendgen, H.
Schneble, H. -M.
Overell, J.
Sauter, A.
Prajapati, K.
Kappos, L.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 234 - 235
[7] Sustained reduction in 48-week confirmed disability progression in patients with PPMS treated with ocrelizumab in the ORATORIO OLE: 8-year follow-up
Wolinsky, J. S.
Vermersch, P.
Hartung, H. -P.
Naismith, R. T.
Airas, L.
Townsend, B.
Schneble, H. -M.
Overell, J.
Sauter, A.
Wang, Q.
Prajapati, K.
Kappos, L.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 101 - 102
[8] Annualized Relapse Rate and Confirmed Disability Progression in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis
Hauser, Stephen
Brochet, Bruno
Montalban, Xavier
Naismith, Robert
Wolinsky, Jerry
Manfrini, Marianna
Garas, Monika
Villoslada, Pablo
Model, Fabian
Hubeaux, Stanislas
Kappos, Ludwig
NEUROLOGY, 2018, 90
[9] Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial
Wolinsky, Jerry S.
Arnold, Douglas L.
Brochet, Bruno
Hartung, Hans-Peter
Montalban, Xavier
Naismith, Robert T.
Manfrini, Marianna
Overell, James
Koendgen, Harold
Sauter, Annette
Bennett, Iain
Hubeaux, Stanislas
Kappos, Ludwig
Hauser, Stephen L.
LANCET NEUROLOGY, 2020, 19 (12): : 998 - 1009
[10] Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial
Fox, Edward J.
Markowitz, Clyde
Applebee, Angela
Montalban, Xavier
Wolinsky, Jerry S.
Belachew, Sihbeshih
Fiore, Damian
Pei, Jinglan
Musch, Bruno
Giovannoni, Gavin
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (14) : 1862 - 1870

← 1 2 3 4 →